β-Blockers

  • Michael M. Givertz
  • Wilson S. Colucci

Abstract

The overall goals in the management of heart failure are to prevent or eliminate symptoms, improve quality of life, and prolong survival. Paradoxically, as has been demonstrated with positive inotropic agents such as vesnarinone and flosequinan, chronic heart failure therapy may improve quality of life and reduce symptoms while increasing mortality. As discussed in Chapter 11, several large randomized controlled trials have demonstrated the beneficial effects of angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor antagonists on exercise tolerance, clinical signs and symptoms, neurohormonal stimulation, quality of life, and survival in patients with chronic heart failure.

Keywords

Heart Failure Left Ventricular Ejection Fraction Chronic Heart Failure Cardiac Index Severe Heart Failure 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Anand IS, Fisher LD, Chiang YT, et aL: Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation 2003, 107: 1278–1283.PubMedCrossRefGoogle Scholar
  2. 2.
    Benedict CR, Shelton B, Johnstone DE, et al.: Prognostic significance of plasma norepinephrine in patients with asymptomatic left ventricular dysfunction. SOLVD Investigators. Circulation 1996, 94:690–697.PubMedCrossRefGoogle Scholar
  3. 3.
    Packer M: Beta-adrenergic blockade in chronic heart failure: principles, progress, and practice. Frog Cardiovasc Dis 1998, 41: 39–52.CrossRefGoogle Scholar
  4. 4.
    Hjalmarson A, Waagstein F: Use of beta-blockers in the treatment of dilated cardiomyopathy. In Heart Failure: Basic Science and Clinical Aspects. Edited by Gwathmey JK, Briggs GM, Allen PD. New York: Marcel Dekker; 1993: 223–251.Google Scholar
  5. 5.
    Hall SA, Cigarroa CG, Marcoux L, et al.: Time course of improvement in left ventricular function, mass and geometry in patients with congestive heart failure treated with beta-adrenergic blockade. J Am Coll Cardiol 1995, 25:1154–1161.PubMedCrossRefGoogle Scholar
  6. 6.
    Doughty RN, Whalley GA, Gamble G, et al.: Left ventricular remodeling with carvedilol in patients with congestive heart failure due to ischemic heart disease. Australia-New Zealand Heart Failure Research Collaborative Group. J Am Coll Cardiol 1997, 29:1060–1066.PubMedCrossRefGoogle Scholar
  7. 7.
    Groenning BA, Nilsson JC, Sondergaard L, et al.: Antiremodeling effects on the left ventricle during beta-blockade with metoprolol in the treatment of chronic heart failure. J Am Coll Cardiol 2000, 36:2072–2080.PubMedCrossRefGoogle Scholar
  8. 8.
    Gheorghiade M, Colucci WS, Swedberg K: Beta-blockers in chronic heart failure. Circulation 2003, 107: 1570–1575.PubMedCrossRefGoogle Scholar
  9. 9.
    Packer M, Bristow MR, Cohn JN, et al.: The effect of carvedilol on morbidity and mortality in patients with chronic heart failure: U.S. Carvedilol Heart Failure Study Group. IV Engl J Med 1996, 334:1349–1355.CrossRefGoogle Scholar
  10. 10.
    Bristow MR, Gilbert EM, Abraham WT, et al.: Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation 1996, 94:2807–2816.PubMedCrossRefGoogle Scholar
  11. 11.
    Heidenreich PA, Lee TT, Massie BM: Effect of beta-blockade on mortality in patients with heart failure: a meta-analysis of randomized clinical trials. J Am Call Cardiol 1997, 30: 27–34.CrossRefGoogle Scholar
  12. 12.
    CIBIS II Investigators and Committees: The Cardiac Insufficiency Bisoprolol Study II (CIBIS-lI): a randomised trial. Lancet 1999, 353: 9–13.CrossRefGoogle Scholar
  13. 13.
    MERIT-HF Study Group: Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999, 353: 2001–2007.CrossRefGoogle Scholar
  14. 14.
    Wikstrand J, Hjalmarson A, Waagstein F, et al.: Dose of metoprolol CR/XL and clinical outcomes in patients with heart failure: analysis of the experience in metoprolol CR/XL randomized intervention trial in chronic heart failure (MERIT-HF). J Ani Coll Cardiol 2002, 40:491–498.CrossRefGoogle Scholar
  15. 15.
    Packer M, Coats AJ, Fowler MB, et al.: Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001, 344:1651–1658.PubMedCrossRefGoogle Scholar
  16. 16.
    Krum H, Roecker EB, Mohacsi P, et al.:Effects of initiating carvedilol in patients with severe chronic heart failure: results from the COPERNICUS Study. JAMA 2003, 289:712–718.PubMedCrossRefGoogle Scholar
  17. 17.
    The CAPRICORN Investigators: Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet 2001, 357: 1385–1390.Google Scholar
  18. 18.
    The Beta-Blocker Evaluation of Survival Trial Investigators: A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med 2001, 344: 1659–1667.CrossRefGoogle Scholar
  19. 19.
    Yancy CW, Fowler MB, Colucci WS, et al.: Race and the response to adrenergic blockade with carvedilol in patients with chronic heart failure. N Engl J Med 2001, 344:1358–1365.CrossRefGoogle Scholar
  20. 20.
    Shekelle PG, Rich MW, Morton SC, et al.: Efficacy of angiotensinconverting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: a meta-analysis of major clinical trials. J Am Coll Cordial 2003, 41:1529–1538.CrossRefGoogle Scholar
  21. 21.
    Poole-Wilson PA, Swedberg K, Cleland JG, et al.: Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 2003, 362:7–13.PubMedCrossRefGoogle Scholar
  22. 22.
    Azevedo ER, Kubo T, Mak S, et al.: Nonselective versus selective beta-adrenergic receptor blockade in congestive heart failure: differential effects on sympathetic activity. Circulation 2001, 104:2194–2199.PubMedCrossRefGoogle Scholar
  23. 23.
    Metra M, Nodari S, D’Aloia A, et al.: Beta-blocker therapy influences the hemodynamic response to inotropic agents in patients with heart failure: a randomized comparison of dobutamine and enoximone before and after chronic treatment with metoprolol or carvedilol. J Am Call Cordial 2002, 40:1248–1258.CrossRefGoogle Scholar
  24. 24.
    Johnson D, Jin Y, Quan FI, et al.: Beta-blockers and angiotensinconverting enzyme inhibitors/receptor blockers prescriptions after hospital discharge for heart failure are associated with decreased mortality in Alberta, Canada. J Am Call Cardial 2003, 42:1438–1445.CrossRefGoogle Scholar
  25. 25.
    Ansari M, Shlipak MG, Heidenreich PA, et al.: Improving guideline adherence: a randomized trial evaluating strategies to increase beta-blocker use in heart failure. Circulation 2003, 107:2799–2804.PubMedCrossRefGoogle Scholar
  26. 26.
    Gattis WA, O’Connor CM, Gallup DS, et al.: Predischarge initiation of carvedilol in patients hospitalized for decompensated heart failure: results of the Initiation Management Predischarge: Process for Assessment of Carvedilol Therapy in Heart Failure (IMPACT-HF) Trial. J Am Call Cordial 2004, 43:1534–1541.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2005

Authors and Affiliations

  • Michael M. Givertz
  • Wilson S. Colucci

There are no affiliations available

Personalised recommendations